about
Taurine: the appeal of a safe amino acid for skeletal muscle disordersEffects of Nandrolone in the Counteraction of Skeletal Muscle Atrophy in a Mouse Model of Muscle Disuse: Molecular Biology and Functional EvaluationNew 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle functionOn the metabolically active form of metaglidasen: improved synthesis and investigation of its peculiar activity on peroxisome proliferator-activated receptors and skeletal musclesHomologation of mexiletine alkyl chain and stereoselective blockade of skeletal muscle sodium channelsDifferent ability of clenbuterol and salbutamol to block sodium channels predicts their therapeutic use in muscle excitability disorders.Angiotensin II modulates mouse skeletal muscle resting conductance to chloride and potassium ions and calcium homeostasis via the AT1 receptor and NADPH oxidaseEffects of taurine analogues on chloride channel conductance of rat skeletal muscle fibers: a structure-activity relationship investigation.Paracrine effects of IGF-1 overexpression on the functional decline due to skeletal muscle disuse: molecular and functional evaluation in hindlimb unloaded MLC/mIgf-1 transgenic micePre-clinical trials in Duchenne dystrophy: what animal models can tell us about potential drug effectiveness.Therapeutic approaches to ion channel diseases.Effects of pleiotrophin overexpression on mouse skeletal muscles in normal loading and in actual and simulated microgravity.Taurine and skeletal muscle disorders.Redox homeostasis, oxidative stress and disuse muscle atrophy.Growth hormone secretagogues exert differential effects on skeletal muscle calcium homeostasis in male rats depending on the peptidyl/nonpeptidyl structure.Statins and fenofibrate affect skeletal muscle chloride conductance in rats by differently impairing ClC-1 channel regulation and expression.Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study.An olive oil-derived antioxidant mixture ameliorates the age-related decline of skeletal muscle function.Structural requisites of 2-(p-chlorophenoxy)propionic acid analogues for activity on native rat skeletal muscle chloride conductance and on heterologously expressed CLC-1.Phosphorylation and IGF-1-mediated dephosphorylation pathways control the activity and the pharmacological properties of skeletal muscle chloride channelsDisuse of rat muscle in vivo reduces protein kinase C activity controlling the sarcolemma chloride conductance.Antioxidant treatment of hindlimb-unloaded mouse counteracts fiber type transition but not atrophy of disused muscles.Is oxidative stress a cause or consequence of disuse muscle atrophy in mice? A proteomic approach in hindlimb-unloaded mice.Molecular requisites for drug binding to muscle CLC-1 and renal CLC-K channel revealed by the use of phenoxy-alkyl derivatives of 2-(p-chlorophenoxy)propionic acid.Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1.Changes of chloride channel regulation in rat skeletal muscle during aging.Decrease in resting calcium and calcium entry associated with slow-to-fast transition in unloaded rat soleus muscle.Investigations of pharmacologic properties of the renal CLC-K1 chloride channel co-expressed with barttin by the use of 2-(p-Chlorophenoxy)propionic acid derivatives and other structurally unrelated chloride channels blockers.New potent mexiletine and tocainide analogues evaluated in vivo and in vitro as antimyotonic agents on the myotonic ADR mouse.The alteration of calcium homeostasis in adult dystrophic mdx muscle fibers is worsened by a chronic exercise in vivo.Fiber type-related changes in rat skeletal muscle calcium homeostasis during aging and restoration by growth hormone.Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum/mitochondria Ca2+-release system.Role of tumour necrosis factor alpha, but not of cyclo-oxygenase-2-derived eicosanoids, on functional and morphological indices of dystrophic progression in mdx mice: a pharmacological approach.Protein kinase C theta (PKCθ) modulates the ClC-1 chloride channel activity and skeletal muscle phenotype: a biophysical and gene expression study in mouse models lacking the PKCθ.Developmental changes of membrane electrical properties of rat skeletal muscle fibers produced by prenatal exposure to carbon monoxide.Recovery of the soleus muscle after short- and long-term disuse induced by hindlimb unloading: effects on the electrical properties and myosin heavy chain profileIon channels in muscle and cardiac hereditary diseases: from gene dysfunction to pharmacological therapyAntimyotonic effects of tocainide enantiomers on skeletal muscle fibers of congenitally myotonic goatsAging-associated down-regulation of ClC-1 expression in skeletal muscle: phenotypic-independent relation to the decrease of chloride conductanceEffects of HMG-CoA reductase inhibitors on excitation–contraction coupling of rat skeletal muscle
P50
Q26799770-4A8A7936-D323-4318-A41B-A254879AB6F4Q27304606-CF999E66-B73E-4267-BE35-DE73987B5537Q27657537-1D66CD43-CB64-4066-96DB-52118B66C03EQ27697692-2ABD046B-729C-4205-BD82-515A1587D277Q28374367-86B5FAC2-C01E-4E05-B998-814DBD33EC34Q34180008-E85513EF-6A4A-4CD8-A0E4-6F572518ECEFQ34295366-F65ADD44-725B-490E-AA6F-0EA04586C95FQ34726549-5E2271F8-9F1C-420B-AD62-8A39C8BE79F2Q34766154-929FAFF5-57A6-46DD-9B45-269BB80336F2Q34807169-7C727048-8EB3-496C-AF7C-733FA1862EC0Q34927551-563E2DA1-20FC-4DAD-A429-3E38E6565148Q34981338-77C0F7A8-CF59-477D-B0B4-9B19130909E6Q35678828-61629B64-7D82-479C-BDB1-17C4027E2EDEQ37841944-99CEC539-BCD9-41EE-A9EA-82E502A42454Q39128776-25C08C5D-ACB4-49D8-8941-6A81EB2B159EQ39883450-631BD54A-D8A2-4BC9-8728-7D1CB9BF7457Q41604256-CA6A5798-25BA-4E70-9363-25EDC9CB525CQ41868299-5DFFFA34-9928-4BD5-8458-996879F85A0DQ42019489-06272351-3DF0-4FA4-A42D-3BBD5FCB5DA2Q42234720-9CF391B2-1450-42F5-9229-7C80B3F0D1E8Q42518795-155C6A66-2858-4FED-B5FC-A5FBC433DDEAQ43179954-4EA4B426-3A8C-4036-B4F0-982BE7086AB2Q43263806-C4308B06-7F68-4A46-894C-54984C823D50Q44072155-D3DAA415-2985-4B00-AFEF-59429DE0A594Q44255035-D19456B2-9F38-4921-83D8-45AF77E79E18Q44416902-064BEEBE-7AE3-4457-8090-4714C62336AEQ44552025-B3454ACD-5000-4BC5-A3EF-FB69AE21E107Q44705255-A549109B-CDFB-4672-A863-DE1A53B40A41Q44946695-0962DAB7-0B0F-4FAF-9BB9-B517F67133AAQ45098242-EDE6B3E4-2377-4530-BCE4-AA026AAB4847Q46695631-FBD0E04B-3206-4802-9507-4B9B7040B396Q50705628-A0693B46-2BAA-4B54-AC0E-485F5F4BE09CQ51007790-7ED504A2-BA01-4D93-B805-147E3C83EC11Q51747566-5A56B058-106C-4562-A179-13020D79A940Q52199384-EA6EC8E2-7BD7-45DA-BDC5-CA5CE00ACA4FQ59467095-972A5A59-A7AA-4EB3-8EED-63A54ABB2958Q59467325-166A6C27-A11A-4BC2-86A8-305CF132256EQ59467346-8FD5BA23-AD35-482F-8728-B0A37EFE825DQ59467401-48F7EB44-5CF3-4202-B11C-428DF9F11838Q59467419-05941A23-050B-44C6-B46F-52A03AC01A64
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sabata Pierno
@ast
Sabata Pierno
@en
Sabata Pierno
@es
Sabata Pierno
@nl
Sabata Pierno
@sl
type
label
Sabata Pierno
@ast
Sabata Pierno
@en
Sabata Pierno
@es
Sabata Pierno
@nl
Sabata Pierno
@sl
prefLabel
Sabata Pierno
@ast
Sabata Pierno
@en
Sabata Pierno
@es
Sabata Pierno
@nl
Sabata Pierno
@sl
P106
P1153
6603923302
P31
P496
0000-0003-3121-2666